Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 12/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677046 | 1.00 | NOD1 (0.54) | NOD1PTGS1GSTK1CCKBRGLO1 | |
| SCHEMBL3796642 | 0.99 | NOD1 (0.56) | NOD1PTGS1GSTK1CCKBRGLO1 | |
| SCHEMBL2787322 | 0.99 | NOD1 (0.56) | NOD1PTGS1GSTK1CCKBRGLO1 | |
| SCHEMBL3798413 | 0.97 | NOD1 (0.52) | NOD1PTGS1GSTK1CCKBRGLO1 | |
| SCHEMBL3796919 | 0.92 | PTGS1 (0.54) | NOD1PTGS1GSTK1CCKBRGLO1 | |
| SCHEMBL8858265 | 0.91 | NOD1 (0.57) | NOD1PTGS1GSTK1CCKBR | |
| SCHEMBL3388427 | 0.90 | PTGS1 (0.54) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL2733937 | 0.89 | PTGS1 (0.47) | NOD1PTGS1GSTK1GLO1 | |
| SCHEMBL8933685 | 0.87 | NOD1 (0.45) | NOD1PTGS1GSTK1CCKBR | |
| SCHEMBL4657010 | 0.87 | PTGS1 (0.56) | NOD1PTGS1GSTK1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2775874-B1 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND THE TREATMENT OF DEGENERATIVE SKIN DISORDERS ESPECIALLY CAUSED BY IONIZING RADIATIONS | SOLOSALE S R L (IT) | 2018-01-10 | — | — | EP | disclosed |
| US-20110160143-A1 | Topical Acyl Glutathione Psoriasis Compositions | N.V. PERRICONE LLC | 2011-06-30 | — | — | US | disclosed |
| EP-0783582-B1 | PROCESS OF PRODUCING $g(b)-LACTAM ANTIBIOTICS APPLYING MICROORGANISMS WITH INCREASED LIGASE ACTIVITY | DSM IP ASSETS BV (NL) | 2005-03-02 | — | — | EP | disclosed |
| US-6180360-B1 | ACYL-COENZYME A SYNTHETASE | GIST-BROCADES (NL) | 2001-01-30 | — | — | US | disclosed |
| US-5942411-A | ISOLATED ACYL-COENZYME A SYNTHETASE FROM PENICILLIUM CHRYSOGENUM WHICH IS MORE ACTIVE TOWARDS PHENOXYACETIC ACID AND PHENYLACETIC ACID THAN ACETIC ACID; FOR EFFICIENT SYNTHESIS OF PENICILLIN G AND V AMONG OTHERS | GIST-BROCADES (NL) | 1999-08-24 | — | — | US | disclosed |
| EP-0783582-A1 | PROCESS OF PRODUCING $g(b)-LACTAM ANTIBIOTICS APPLYING MICROORGANISMS WITH INCREASED LIGASE ACTIVITY | GIST-BROCADES B.V. (NL) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010085-A1 | PROCESS OF PRODUCING β-LACTAM ANTIBIOTICS APPLYING MICROORGANISMS WITH INCREASED LIGASE ACTIVITY | GIST-BROCADES B.V. (NL) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160143-A1 | Topical Acyl Glutathione Psoriasis Compositions | GSTA2, GSTA1, GSTM2 | NOD1 2653/4885PTGS1 72/4885GSTK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.